|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
4
|
Howington JA, Blum MG, Chang AC, Balekian
AA and Murthy SC: Treatment of stage I and II non-small cell lung
cancer: Diagnosis and management of lung cancer, 3rd ed: American
College of Chest Physicians evidence-based clinical practice
guidelines. Chest. 143(Suppl 5): e278S–e313S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Inoue A, Kobayashi K, Maemondo M, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al North-East Japan Study Group: Updated overall survival
results from a randomized phase III trial comparing gefitinib with
carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer
with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 24:54–59.
2013. View Article : Google Scholar
|
|
6
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sawyers C: Targeted cancer therapy.
Nature. 432:294–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kris MG, Natale RB, Herbst RS, Lynch TJ
Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H,
Sandler A, et al: Efficacy of gefitinib, an inhibitor of the
epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer: A randomized trial. JAMA.
290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Janku F, Stewart DJ and Kurzrock R:
Targeted therapy in non-small-cell lung cancer - is it becoming a
reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Antonicelli A, Cafarotti S, Indini A,
Galli A, Russo A, Cesario A, Lococo FM, Russo P, Mainini AF,
Bonifati LG, et al: EGFR-targeted therapy for non-small cell lung
cancer: Focus on EGFR oncogenic mutation. Int J Med Sci.
10:320–330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arvey A, van der Veeken J, Samstein RM,
Feng Y, Stamatoyannopoulos JA and Rudensky AY: Inflammation-induced
repression of chromatin bound by the transcription factor Foxp3 in
regulatory T cells. Nat Immunol. 15:580–587. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Samstein RM, Arvey A, Josefowicz SZ, Peng
X, Reynolds A, Sandstrom R, Neph S, Sabo P, Kim JM, Liao W, et al:
Foxp3 exploits a pre-existent enhancer landscape for regulatory T
cell lineage specification. Cell. 151:153–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katoh H, Zheng P and Liu Y: FOXP3: Genetic
and epigenetic implications for autoimmunity. J Autoimmun.
41:72–78. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fleskens V, Mokry M, van der Leun AM,
Huppelschoten S, Pals CE, Peeters J, Coenen S, Cardoso BA, Barata
JT, van Loosdregt J, et al: FOXP3 can modulate TAL1 transcriptional
activity through interaction with LMO2. Oncogene. Dec 21–2015.Epub
ahead of print. PubMed/NCBI
|
|
16
|
Liu R, Liu C, Chen D, Yang WH, Liu X, Liu
CG, Dugas CM, Tang F, Zheng P, Liu Y, et al: Foxp3 controls an
miR-146/NF-κB negative feedback loop that inhibits apoptosis in
breast cancer cells. Cancer Res. 75:1703–1713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao D, Long XD, Lu TF, Wang T, Zhang WW,
Liu YX, Cui XL, Dai HJ, Xue F and Xia Q: Metformin decreases IL-22
secretion to suppress tumor growth in an orthotopic mouse model of
hepatocellular carcinoma. Int J Cancer. 136:2556–2565. 2015.
View Article : Google Scholar
|
|
18
|
Luo Q, Zhang Y, Wang N, Jin G, Jin H, Gu
D, Tao X, Huo X, Ge T, Cong W, et al: Leukemia inhibitory factor
receptor is a novel immunomarker in distinction of
well-differentiated HCC from dysplastic nodules. Oncotarget.
6:6989–6999. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS,
Hwang SG, An S, Yoon G, Gye MC, Yi JM, et al: Claudin-1 induces
epithelial-mesenchymal transition through activation of the
c-Abl-ERK signaling pathway in human liver cells. Oncogene.
32:4873–4882. 2013. View Article : Google Scholar
|
|
20
|
Schlegel NC, von Planta A, Widmer DS,
Dummer R and Christofori G: PI3K signalling is required for a
TGFβ-induced epithelial-mesenchymal-like transition (EMT-like) in
human melanoma cells. Exp Dermatol. 24:22–28. 2015. View Article : Google Scholar
|
|
21
|
Liu R-Y, Zeng Y, Lei Z, Wang L, Yang H,
Liu Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014.PubMed/NCBI
|
|
22
|
Li C-W, Xia W, Huo L, Lim SO, Wu Y, Hsu
JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, et al:
Epithelial-mesenchymal transition induced by TNF-α requires
NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res.
72:1290–1300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bennett CL, Christie J, Ramsdell F,
Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT,
Chance PF and Ochs HD: The immune dysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused
by mutations of FOXP3. Nat Genet. 27:20–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Perrone G, Ruffini PA, Catalano V, Spino
C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V,
Alessandroni P, et al: Intratumoural FOXP3-positive regulatory T
cells are associated with adverse prognosis in radically resected
gastric cancer. Eur J Cancer. 44:1875–1882. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Merlo A, Casalini P, Carcangiu ML,
Malventano C, Triulzi T, Mènard S, Tagliabue E and Balsari A: FOXP3
expression and overall survival in breast cancer. J Clin Oncol.
27:1746–1752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li W, Wang L, Katoh H, Liu R, Zheng P and
Liu Y: Identification of a tumor suppressor relay between the FOXP3
and the Hippo pathways in breast and prostate cancers. Cancer Res.
71:2162–2171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang L, Liu R, Li W, Chen C, Katoh H, Chen
GY, McNally B, Lin L, Zhou P, Zuo T, et al: Somatic single hits
inactivate the X-linked tumor suppressor FOXP3 in the prostate.
Cancer Cell. 16:336–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zavadil J, Haley J, Kalluri R, Muthuswamy
SK and Thompson E: Epithelial-mesenchymal transition. Cancer Res.
68:9574–9577. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cañadas I, Rojo F, Taus Á, Arpí O,
Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M, et
al: Targeting epithelial-to-mesenchymal transition with Met
inhibitors reverts chemoresistance in small cell lung cancer. Clin
Cancer Res. 20:938–950. 2014. View Article : Google Scholar
|
|
33
|
Serresi M, Gargiulo G, Proost N, Siteur B,
Cesaroni M, Koppens M, Xie H, Sutherland KD, Hulsman D, Citterio E,
et al: Polycomb repressive complex 2 is a barrier to KRAS-driven
inflammation and epithelial-mesenchymal transition in non-small
cell lung cancer. Cancer Cell. 29:17–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng Z-X, Wang D-W, Liu T, Liu WX, Xia
WB, Xu J, Zhang YH, Qu YK, Guo LQ, Ding L, et al: Effects of the
HIF-1α and NF-κB loop on epithelial-mesenchymal transition and
chemoresistance induced by hypoxia in pancreatic cancer cells.
Oncol Rep. 31:1891–1898. 2014.PubMed/NCBI
|
|
35
|
Li J, Deng Z, Wang Z, Wang D, Zhang L, Su
Q, Lai Y, Li B, Luo Z, Chen X, et al: Zipper-interacting protein
kinase promotes epithelial-mesenchymal transition, invasion and
metastasis through AKT and NF-κB signaling and is associated with
metastasis and poor prognosis in gastric cancer patients.
Oncotarget. 6:8323–8338. 2015. View Article : Google Scholar : PubMed/NCBI
|
